MX347656B - Inversion de los efectos del micro-ambiente de tumor utilizando receptores de citocina quimericos. - Google Patents
Inversion de los efectos del micro-ambiente de tumor utilizando receptores de citocina quimericos.Info
- Publication number
- MX347656B MX347656B MX2013011742A MX2013011742A MX347656B MX 347656 B MX347656 B MX 347656B MX 2013011742 A MX2013011742 A MX 2013011742A MX 2013011742 A MX2013011742 A MX 2013011742A MX 347656 B MX347656 B MX 347656B
- Authority
- MX
- Mexico
- Prior art keywords
- reversing
- effects
- cells
- tumor microenvironment
- cytokine receptors
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 102000003675 cytokine receptors Human genes 0.000 title 1
- 108010057085 cytokine receptors Proteins 0.000 title 1
- 102000004127 Cytokines Human genes 0.000 abstract 2
- 108090000695 Cytokines Proteins 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 1
- 102000003814 Interleukin-10 Human genes 0.000 abstract 1
- 108090000174 Interleukin-10 Proteins 0.000 abstract 1
- 102000003816 Interleukin-13 Human genes 0.000 abstract 1
- 108090000176 Interleukin-13 Proteins 0.000 abstract 1
- 210000000447 Th1 cell Anatomy 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 108700010039 chimeric receptor Proteins 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000009877 rendering Methods 0.000 abstract 1
- 230000002463 transducing effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001188—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001189—PRAME
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4635—Cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464448—Regulators of development
- A61K39/46445—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464457—Telomerase or [telomerase reverse transcriptase [TERT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464469—Tumor associated carbohydrates
- A61K39/46447—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46448—Cancer antigens from embryonic or fetal origin
- A61K39/464482—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464486—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464488—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464489—PRAME
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/54—Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2304—Interleukin-4 (IL-4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2306—Interleukin-6 (IL-6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2312—Interleukin-12 (IL-12)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
La presente invención se refiere a una célula del sistema inmune que comprende un receptor de citosina quimérico, caracterizada porque comprende un exodominio de unión a citosina y un endodominio de transducción de señal, en donde el exodominio es el exodominio del receptor IL4 y el endodominio es el endodominio del receptor IL7 o el exodominio es el exodominio del receptor IL13 y el endodominio es el endodominio del receptor IL2, en donde la célula es una célula T primaria, linfocito T, o una célula NK.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161473457P | 2011-04-08 | 2011-04-08 | |
PCT/US2012/032322 WO2012138858A1 (en) | 2011-04-08 | 2012-04-05 | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013011742A MX2013011742A (es) | 2014-03-27 |
MX347656B true MX347656B (es) | 2017-05-08 |
Family
ID=46969548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013011742A MX347656B (es) | 2011-04-08 | 2012-04-05 | Inversion de los efectos del micro-ambiente de tumor utilizando receptores de citocina quimericos. |
Country Status (13)
Country | Link |
---|---|
US (2) | US10548921B2 (es) |
EP (2) | EP2694640B1 (es) |
JP (3) | JP6066991B2 (es) |
CN (2) | CN107164330A (es) |
AU (3) | AU2012240135B2 (es) |
CA (1) | CA2832569A1 (es) |
DK (1) | DK2694640T3 (es) |
ES (1) | ES2649967T3 (es) |
HK (1) | HK1245840A1 (es) |
MX (1) | MX347656B (es) |
NO (1) | NO2724929T3 (es) |
NZ (3) | NZ723731A (es) |
WO (1) | WO2012138858A1 (es) |
Families Citing this family (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9249423B2 (en) | 2007-02-02 | 2016-02-02 | Yale University | Method of de-differentiating and re-differentiating somatic cells using RNA |
US10155038B2 (en) | 2007-02-02 | 2018-12-18 | Yale University | Cells prepared by transient transfection and methods of use thereof |
US8956860B2 (en) | 2009-12-08 | 2015-02-17 | Juan F. Vera | Methods of cell culture for adoptive cell therapy |
KR102062407B1 (ko) | 2010-12-09 | 2020-01-03 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도 |
JP2015519080A (ja) * | 2012-06-11 | 2015-07-09 | ウィルソン ウォルフ マニュファクチャリング コーポレイションWilson Wolf Manufacturing Corporation | 養子細胞療法のための改良型細胞培養方法 |
AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
NZ750426A (en) * | 2013-02-06 | 2020-06-26 | Celgene Corp | Modified t lymphocytes having improved specificity |
PT2958943T (pt) | 2013-02-20 | 2019-12-17 | Novartis Ag | Tratamento do cancro usando recetor de antigénios quiméricos anti-egfrviii humanizados |
US9573988B2 (en) | 2013-02-20 | 2017-02-21 | Novartis Ag | Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells |
EP2970426B1 (en) | 2013-03-15 | 2019-08-28 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
AU2014240083C1 (en) | 2013-03-15 | 2019-10-24 | Celgene Corporation | Modified T lymphocytes |
TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗-cd19嵌合抗原受體治療癌症 |
EP2986636B1 (en) | 2013-04-17 | 2018-11-14 | Baylor College Of Medicine | Immunosuppressive tgf-beta signal converter |
JP2016526536A (ja) * | 2013-06-14 | 2016-09-05 | ザ ユニバーシティ オブ ヒューストン システム | 修飾されたキメラ抗原受容体による腫瘍新生血管構造の標的化 |
WO2015010096A1 (en) * | 2013-07-18 | 2015-01-22 | Baylor College Of Medicine | Method of enhancing potency of immune cells |
CA3225453A1 (en) | 2013-12-19 | 2015-06-25 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
JP6793902B2 (ja) | 2013-12-20 | 2020-12-02 | ノバルティス アーゲー | 調節可能キメラ抗原受容体 |
EP4303229A3 (en) | 2014-01-21 | 2024-04-17 | Novartis AG | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
IL293603B2 (en) | 2014-04-07 | 2024-03-01 | Novartis Ag | Cancer treatment using chimeric antigen receptor (CAR) against CD19 |
JP2017514471A (ja) * | 2014-04-23 | 2017-06-08 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | キメラ抗原受容体(car)並びにその製造及び使用方法 |
TWI718992B (zh) | 2014-07-21 | 2021-02-21 | 瑞士商諾華公司 | 使用cll-1嵌合抗原受體治療癌症 |
CN112481283A (zh) | 2014-07-21 | 2021-03-12 | 诺华股份有限公司 | 使用cd33嵌合抗原受体治疗癌症 |
US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
CN106687483B (zh) | 2014-07-21 | 2020-12-04 | 诺华股份有限公司 | 使用人源化抗-bcma嵌合抗原受体治疗癌症 |
JP6631865B2 (ja) * | 2014-08-11 | 2020-01-15 | 日本化薬株式会社 | TGFβ阻害機能を持つキメラタンパク質 |
MY189028A (en) | 2014-08-19 | 2022-01-20 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
DK3194443T3 (da) | 2014-09-17 | 2021-09-27 | Novartis Ag | Målretning af cytotoksiske celler med kimære receptorer i forbindelse med adoptiv immunterapi |
SG11201702895SA (en) | 2014-10-08 | 2017-05-30 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
MA41538A (fr) * | 2014-10-17 | 2017-12-26 | Baylor College Medicine | Cellules immunitaires bipartites et tripartites de signalisation |
KR20170093254A (ko) | 2014-12-29 | 2017-08-14 | 노파르티스 아게 | 키메라 항원 수용체-발현 세포를 제조하는 방법 |
WO2016115482A1 (en) | 2015-01-16 | 2016-07-21 | Novartis Pharma Ag | Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor |
AU2015380397B2 (en) * | 2015-01-31 | 2021-10-21 | The Trustees Of The University Of Pennsylvania | Compositions and methods for T cell delivery of therapeutic molecules |
WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
IL297418B2 (en) | 2015-02-18 | 2023-11-01 | Enlivex Therapeutics Rdo Ltd | Combined immunotherapy and cytokine control therapy for cancer treatment |
US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
JP7362249B2 (ja) * | 2015-03-20 | 2023-10-17 | チルドレンズ ナショナル メディカル センター | ナイーブt細胞集団からのウイルスまたは他の抗原に特異的なt細胞の生成 |
SI3280729T1 (sl) | 2015-04-08 | 2022-09-30 | Novartis Ag | Terapije CD20, terapije CD22 in kombinacija terapij s celico, ki izraža himerni antigenski receptor CD19 (CAR) |
JP7114457B2 (ja) | 2015-04-17 | 2022-08-08 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | キメラ抗原受容体発現細胞の有効性および増殖を改善するための方法 |
IL287500B2 (en) | 2015-04-21 | 2023-12-01 | Enlivex Therapeutics Rdo Ltd | Therapeutic preparations from pooled apoptotic blood cells and their use |
CN104910279B (zh) * | 2015-06-05 | 2019-02-22 | 重庆精准生物技术有限公司 | 靶向癌胚抗原的嵌合抗原受体、慢病毒表达载体及其制备方法和应用 |
AR105433A1 (es) | 2015-07-21 | 2017-10-04 | Novartis Ag | Métodos para mejorar la eficacia y expansión de las células inmunes |
EP3331913A1 (en) | 2015-08-07 | 2018-06-13 | Novartis AG | Treatment of cancer using chimeric cd3 receptor proteins |
GB201514875D0 (en) | 2015-08-20 | 2015-10-07 | Autolus Ltd | Receptor |
JP6905163B2 (ja) | 2015-09-03 | 2021-07-21 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | サイトカイン放出症候群を予測するバイオマーカー |
GB201518816D0 (en) * | 2015-10-23 | 2015-12-09 | Autolus Ltd | Receptor |
JP7082055B2 (ja) | 2015-12-22 | 2022-06-07 | ノバルティス アーゲー | 抗癌治療における組み合わせ使用のためのメソテリンキメラ抗原受容体(car)およびpd-l1阻害剤に対する抗体 |
US11730761B2 (en) | 2016-02-18 | 2023-08-22 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
WO2018161064A1 (en) * | 2017-03-03 | 2018-09-07 | F1 Oncology, Inc. | Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof |
WO2017165683A1 (en) | 2016-03-23 | 2017-09-28 | Novartis Ag | Cell secreted minibodies and uses thereof |
US20190183936A1 (en) * | 2016-08-26 | 2019-06-20 | Baylor College Of Medicine | Constitutively active cytokine receptors for cell therapy |
AR110676A1 (es) | 2016-10-07 | 2019-04-24 | Novartis Ag | Tratamiento del cáncer utilizando receptores de antígenos quiméricos |
CA3041284A1 (en) | 2016-10-20 | 2018-04-26 | Celgene Corporation | Cereblon-based heterodimerizable chimeric antigen receptors |
JP7263235B2 (ja) | 2016-11-17 | 2023-04-24 | 2セブンティ バイオ インコーポレイテッド | TGFβシグナルコンバーター |
WO2018140725A1 (en) | 2017-01-26 | 2018-08-02 | Novartis Ag | Cd28 compositions and methods for chimeric antigen receptor therapy |
GB201702617D0 (en) * | 2017-02-17 | 2017-04-05 | Autolus Ltd | Receptor |
EP3595706A1 (en) | 2017-03-17 | 2020-01-22 | Fred Hutchinson Cancer Research Center | Immunomodulatory fusion proteins and uses thereof |
KR20190130608A (ko) | 2017-03-22 | 2019-11-22 | 노파르티스 아게 | 면역종양학을 위한 조성물 및 방법 |
EP3610000A1 (en) | 2017-04-13 | 2020-02-19 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
CN109880803A (zh) * | 2017-12-06 | 2019-06-14 | 科济生物医药(上海)有限公司 | 嵌合蛋白、表达嵌合蛋白的免疫效应细胞及其应用 |
KR20200128054A (ko) * | 2018-03-02 | 2020-11-11 | 알로젠 테라퓨틱스 인코포레이티드 | 유도성 키메라 사이토카인 수용체 |
AU2019231205A1 (en) | 2018-03-06 | 2020-09-24 | The Trustees Of The University Of Pennsylvania | Prostate-specific membrane antigen cars and methods of use thereof |
EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
WO2019241426A1 (en) | 2018-06-13 | 2019-12-19 | Novartis Ag | Bcma chimeric antigen receptors and uses thereof |
CN110615843B (zh) * | 2018-06-20 | 2023-05-09 | 上海隆耀生物科技有限公司 | 一种包含第三信号受体的嵌合抗原受体及其应用 |
US11419898B2 (en) | 2018-10-17 | 2022-08-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
EP3866813A4 (en) | 2018-10-17 | 2022-08-03 | Senti Biosciences, Inc. | COMBINATORY CANCER IMMUNOTHERAPY |
US20200147137A1 (en) * | 2018-11-08 | 2020-05-14 | WUGEN, Inc. | Compositions and methods for treatment of cancer |
CN109735558B (zh) * | 2018-12-12 | 2022-04-15 | 中南大学 | 一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用 |
JP2022522654A (ja) | 2019-03-01 | 2022-04-20 | アロジーン セラピューティクス,インコーポレイテッド | Pd-1外部ドメインを担持するキメラサイトカイン受容体 |
CA3149421A1 (en) | 2019-08-30 | 2021-03-04 | Yale University | Compositions and methods for delivery of nucleic acids to cells |
KR102275668B1 (ko) * | 2019-09-26 | 2021-07-12 | 충북대학교 산학협력단 | 면역신호의 변환이 가능한 키메릭 사이토카인 수용체, 이를 발현하는 면역세포 및 이의 항암 용도 |
EP4110801A1 (en) | 2020-02-25 | 2023-01-04 | Quell Therapeutics Limited | Chimeric receptors for use in engineered cells |
EP4204002A1 (en) | 2020-08-31 | 2023-07-05 | Yale University | Compositions and methods for delivery of nucleic acids to cells |
WO2023196997A2 (en) | 2022-04-08 | 2023-10-12 | 2Seventy Bio, Inc. | Multipartite receptor and signaling complexes |
CN116496417B (zh) * | 2023-06-27 | 2023-10-10 | 北京市肿瘤防治研究所 | 含有膜型il7的融合蛋白及t细胞 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08511000A (ja) * | 1993-04-06 | 1996-11-19 | フレッド ハッチンソン キャンサー リサーチ センター | リンパ球におけるキメラサイトカインレセプター |
DE69739951D1 (de) | 1996-03-04 | 2010-09-16 | Calyx Bio Ventures Inc | Modifizierte schnellvermehrungsmethode ('modified-rem') zur in vitro vermehrung von t-lymphozyten |
US6130087A (en) | 1996-10-07 | 2000-10-10 | Fordham University | Methods for generating cytotoxic T cells in vitro |
CN1842346A (zh) | 2001-01-12 | 2006-10-04 | 塞托凯恩药物科学公司 | 由巨噬细胞迁移抑制因子调节细胞毒性淋巴细胞反应 |
WO2002088334A1 (en) * | 2001-04-30 | 2002-11-07 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
US20090257994A1 (en) * | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
US7235392B2 (en) | 2001-12-07 | 2007-06-26 | The Ohio State University Research Foundation | Apoptotic EBV-transformed lymphocytes, a therapeutic agent for post-transplant lymphoproliferative disorder |
AU2003278744B2 (en) | 2002-08-28 | 2010-07-29 | Harbor Biosciences, Inc. | Therapeutic treatment methods |
US7371570B2 (en) | 2002-11-01 | 2008-05-13 | Cell Genesys, Inc. | Cell-specific adenovirus vector comprising EBV-specific promoter |
JP2004315381A (ja) * | 2003-04-11 | 2004-11-11 | Japan Science & Technology Agency | ナチュラルキラーT細胞のインターロイキン18による刺激を利用した免疫疾患治療薬剤および治療キット、並びにIgE産生の制御方法 |
US7435592B2 (en) * | 2003-05-13 | 2008-10-14 | Immunovative Therapies, Ltd. | Compositions for allogeneic cell therapy |
DE602004031341D1 (de) * | 2003-07-21 | 2011-03-24 | Transgene Sa | Multifunktionelle cytokine |
JP2009500346A (ja) * | 2005-06-29 | 2009-01-08 | ユニバーシティー・オブ・マイアミ | 癌処置用の抗体−免疫細胞リガンド融合タンパク質 |
GB0917090D0 (en) | 2009-09-29 | 2009-11-11 | Ucl Biomedica Plc | T-cell receptor |
ES2774160T3 (es) | 2012-02-13 | 2020-07-17 | Seattle Childrens Hospital D/B/A Seattle Childrens Res Institute | Receptores de antígenos quiméricos biespecíficos y usos terapéuticos de los mismos |
AU2014368383B2 (en) | 2013-12-20 | 2020-01-16 | Cellectis | Method of engineering multi-input signal sensitive T cell for immunotherapy |
-
2012
- 2012-04-05 NZ NZ723731A patent/NZ723731A/en not_active IP Right Cessation
- 2012-04-05 EP EP12767723.5A patent/EP2694640B1/en active Active
- 2012-04-05 US US14/110,582 patent/US10548921B2/en active Active
- 2012-04-05 ES ES12767723.5T patent/ES2649967T3/es active Active
- 2012-04-05 MX MX2013011742A patent/MX347656B/es active IP Right Grant
- 2012-04-05 CN CN201710136120.8A patent/CN107164330A/zh active Pending
- 2012-04-05 NZ NZ710810A patent/NZ710810A/en not_active IP Right Cessation
- 2012-04-05 WO PCT/US2012/032322 patent/WO2012138858A1/en active Application Filing
- 2012-04-05 AU AU2012240135A patent/AU2012240135B2/en not_active Ceased
- 2012-04-05 EP EP17190649.8A patent/EP3305890B1/en active Active
- 2012-04-05 NZ NZ616405A patent/NZ616405A/en not_active IP Right Cessation
- 2012-04-05 DK DK12767723.5T patent/DK2694640T3/da active
- 2012-04-05 JP JP2014503979A patent/JP6066991B2/ja not_active Expired - Fee Related
- 2012-04-05 CA CA2832569A patent/CA2832569A1/en active Pending
- 2012-04-05 CN CN201280024856.1A patent/CN103582699B/zh active Active
-
2013
- 2013-08-08 NO NO13003957A patent/NO2724929T3/no unknown
-
2014
- 2014-08-07 HK HK18105460.0A patent/HK1245840A1/zh unknown
-
2016
- 2016-11-01 AU AU2016253549A patent/AU2016253549B2/en not_active Ceased
- 2016-12-20 JP JP2016246100A patent/JP6297129B2/ja active Active
-
2018
- 2018-02-20 JP JP2018027460A patent/JP2018108091A/ja active Pending
- 2018-07-04 AU AU2018204850A patent/AU2018204850B2/en not_active Ceased
-
2020
- 2020-01-15 US US16/743,968 patent/US11717538B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
NO2724929T3 (es) | 2018-04-07 |
CN103582699B (zh) | 2017-03-22 |
EP3305890B1 (en) | 2023-08-23 |
EP2694640A1 (en) | 2014-02-12 |
JP2018108091A (ja) | 2018-07-12 |
HK1245840A1 (zh) | 2018-08-31 |
EP3305890A1 (en) | 2018-04-11 |
JP6297129B2 (ja) | 2018-03-20 |
JP6066991B2 (ja) | 2017-01-25 |
AU2018204850A1 (en) | 2018-07-26 |
EP2694640A4 (en) | 2014-10-01 |
AU2012240135A1 (en) | 2013-10-24 |
AU2016253549A1 (en) | 2016-11-17 |
JP2014512183A (ja) | 2014-05-22 |
CA2832569A1 (en) | 2012-10-11 |
US10548921B2 (en) | 2020-02-04 |
CN103582699A (zh) | 2014-02-12 |
AU2016253549B2 (en) | 2018-04-05 |
CN107164330A (zh) | 2017-09-15 |
NZ710810A (en) | 2016-09-30 |
EP2694640B1 (en) | 2017-10-18 |
AU2018204850B2 (en) | 2020-03-05 |
JP2017093445A (ja) | 2017-06-01 |
US11717538B2 (en) | 2023-08-08 |
MX2013011742A (es) | 2014-03-27 |
NZ723731A (en) | 2020-05-29 |
WO2012138858A1 (en) | 2012-10-11 |
US20140050709A1 (en) | 2014-02-20 |
ES2649967T3 (es) | 2018-01-16 |
NZ616405A (en) | 2015-11-27 |
AU2012240135B2 (en) | 2016-09-08 |
DK2694640T3 (da) | 2017-11-20 |
US20200197437A1 (en) | 2020-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX347656B (es) | Inversion de los efectos del micro-ambiente de tumor utilizando receptores de citocina quimericos. | |
CY1118668T1 (el) | Ανοσοσυζευγματα εναντι υποδοχεα φολικου οξεος 1 και χρησεις αυτων | |
PH12015502439A1 (en) | Anti-cd38 antibodies and fusions to attenuated inferferon alpha-2b | |
PH12017501039A1 (en) | Antibodies targeting g-protein coupled receptor and methods of use | |
PH12017500268A1 (en) | Antibodies and chimeric antigen receptors specific for cd19 | |
AR090263A1 (es) | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma | |
MX2019008503A (es) | Receptores de antigenos quimericos contra axl o ror2 y metodos de uso de los mismos. | |
MX2013004761A (es) | Nuevas moleculas de union al receptor del factor de crecimiento epidermico (egfr) e inmunoconjugados de estas. | |
MX2013004899A (es) | Composicion de anticuerpos pan-her. | |
TN2012000512A1 (en) | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies | |
NZ610976A (en) | Anti-mesothelin antibodies and immunoconjugates | |
NZ604003A (en) | Monoclonal antibodies against her2 | |
MX349057B (es) | Agente terapeutico que induce citotoxicidad. | |
MY173839A (en) | Cd37-binding molecules and immunoconjugates thereof | |
SG178991A1 (en) | Anti-gitr antibodies | |
NZ595641A (en) | Humanized anti-egfl7 antibodies and methods using same | |
BR112013005145A2 (pt) | anticorpos anti-cxcl13 e métodos para seu uso | |
MX343580B (es) | Anticuerpos contra el g-csfr y sus usos. | |
EA201991027A9 (ru) | АНТИТЕЛА ПРОТИВ CD38 И СЛИТЫЕ БЕЛКИ С ОСЛАБЛЕННЫМ ИНТЕРФЕРОНОМ АЛЬФА-2b | |
NZ742073A (en) | Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b | |
NZ740956A (en) | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors | |
TR201905240T4 (tr) | LIV-1'e hümanize edilmiş antikorlar ve bunların kanserin tedavisinde kullanımı. | |
NZ757754A (en) | Antibodies that bind csf1r |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |